Clinical Trials Directory

Trials / Completed

CompletedNCT01375452

Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions

An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) of Dr.Reddy's Laboratories Ltd and Femara 2.5 mg Tablets (Reference)of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fasting Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Dr. Reddy's Laboratories Limited · Industry
Sex
Female
Age
40 Years – 69 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.

Detailed description

An Open Label, Balanced, Randomized,Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative oral bioavailability study in healthy, post menopausal women subjects under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGLetrozoleLetrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited

Timeline

Start date
2008-03-01
Primary completion
2008-05-01
Completion
2008-05-01
First posted
2011-06-17
Last updated
2011-06-27

Source: ClinicalTrials.gov record NCT01375452. Inclusion in this directory is not an endorsement.

Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions (NCT01375452) · Clinical Trials Directory